CAUTION–Investigational Device. Limited by United States Law to Investigational Use.
Corvia Medical, Inc., is dedicated to revolutionizing the treatment of heart failure with first-in-class structural heart devices. The company has developed the world’s first transcatheter device designed to treat heart failure with preserved (HFpEF) or mid-range (HFmrEF) ejection fraction, previously known as diastolic heart failure (DHF). The innovative InterAtrial Shunt Device (IASD®) is clinically proven to reduce elevated left atrial pressure (LAp), which is the main cause of heart failure symptoms.
Corvia Medical Enters Into Agreement With Edwards Lifesciences, The Global Leader In Structural Heart Innovation TEWKSBURY, MA – March 11, 2019— Corvia Medical, Inc., a privately-held company with a first-in-class structural heart device to treat heart failure, today announced it has entered into an agreement with Edwards Lifesciences. The agreement includes a $35 million investment […]
Corvia Medical is enrolling patients in the REDUCE LAP HF II Study. To learn more, visit treatmyheartfailure.com.